ERBB2 and neoplasm: It was found that in patients with advanced HER2+ breast cancer treated with docetaxel, trastuzumab and pertuzumab or placebo, higher TIL levels were significantly associated with improved OS.24 These data suggested that the prognostic effect of anti-tumour immunity also extends to the advanced setting.